- Home
- FSUN vs OCS Comparison
FSUN vs OCS Comparison
Compare FSUN & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSUN
- OCS
- Stock Information
- Founded
- FSUN 1892
- OCS 2003
- Country
- FSUN United States
- OCS Switzerland
- Employees
- FSUN N/A
- OCS N/A
- Industry
- FSUN Major Banks
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- FSUN Finance
- OCS Health Care
- Exchange
- FSUN Nasdaq
- OCS Nasdaq
- Market Cap
- FSUN 1.1B
- OCS 916.3M
- IPO Year
- FSUN N/A
- OCS N/A
- Fundamental
- Price
- FSUN $41.33
- OCS $21.41
- Analyst Decision
- FSUN Buy
- OCS Strong Buy
- Analyst Count
- FSUN 3
- OCS 5
- Target Price
- FSUN $49.00
- OCS $28.80
- AVG Volume (30 Days)
- FSUN 71.6K
- OCS 64.5K
- Earning Date
- FSUN 01-27-2025
- OCS 03-17-2025
- Dividend Yield
- FSUN N/A
- OCS N/A
- EPS Growth
- FSUN N/A
- OCS N/A
- EPS
- FSUN 2.69
- OCS N/A
- Revenue
- FSUN $359,152,000.00
- OCS $1,027,571.00
- Revenue This Year
- FSUN N/A
- OCS $7.98
- Revenue Next Year
- FSUN $7.28
- OCS $853.39
- P/E Ratio
- FSUN $15.36
- OCS N/A
- Revenue Growth
- FSUN 1.38
- OCS N/A
- 52 Week Low
- FSUN $33.31
- OCS $10.55
- 52 Week High
- FSUN $45.32
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- FSUN 49.25
- OCS 52.07
- Support Level
- FSUN $38.25
- OCS $20.95
- Resistance Level
- FSUN $44.98
- OCS $21.86
- Average True Range (ATR)
- FSUN 1.98
- OCS 0.56
- MACD
- FSUN -0.18
- OCS -0.26
- Stochastic Oscillator
- FSUN 43.56
- OCS 56.18
About FSUN FirstSun Capital Bancorp
Firstsun Capital Bancorp is the financial holding company for Sunflower Bank, National Association. It provides a full range of deposit, lending, treasury management, wealth management and online banking products and services. The company operates in two segments - Banking operations and Mortgage operations, out of which the majority of the revenue is generated from the Banking operations segment.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.